E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro–B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy
W.H. Wilson Tang,Steven R. Steinhubl,Frederick Van Lente,Danielle M. Brennan,Ellen McErlean,Anjli Maroo,Gary S. Francis,Eric J. Topol +7 more
TL;DR: In patients undergoing a nonurgent PCI, NT-proBNP levels may provide important prognostic value for death and MI, even in patients with preserved cardiac function, but baseline NT- ProBNP Levels were unable to identify patients with enhanced benefit from pre-procedural and prolonged clopidogrel therapy.
Journal ArticleDOI
Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I and -III trials
Mauricio G. Cohen,Christopher B. Granger,E. Magnus Ohman,Amanda Stebbins,Liliana Grinfeld,Arturo Cagide,Marcelo V Elizari,Amadeo Betriu,David F. Kong,Eric J. Topol,Robert M. Califf +10 more
TL;DR: In this paper, the differences in the process of care and clinical outcomes between Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI) were described.
Journal ArticleDOI
Miscues on the “lack of MEF2A mutations” in coronary artery disease
TL;DR: T careful analysis of family data suggests that the available clinical data are insufficient to make any conclusions and certainly does not support the author’s conclusion that the 21-bp deletion of MEF2A does not cosegregate with the disease and does not cause CAD.
Journal Article
Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time
TL;DR: It was concluded that subthreshold ACTs with high APTTs occur frequently, suggesting the improved suitability of ACT for intraprocedural monitoring of anticoagulation status.
Journal ArticleDOI
Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting
TL;DR: In this model, local adventitial hirulog delivery at the dose and delivery rate used may reduce, but does not prevent, thrombus formation and does not reduce the severity of neointimal thickening after carotid stent implantation.